Dynacor Produces 17,125 oz of Gold in Q1-2017

MONTREAL, QUEBEC--( April 20, 2017) - Dynacor Gold Mines Inc. (TSX:DNG) (OTC:DNGDF) (Dynacor or the Corporation) is pleased to report that its 1st quarter gold production reached 17,125 oz. This represents an increase of 1,318 ounces of gold, as compared to Q1-2016 (15,807 oz), despite the extreme weather conditions in northern and central Peru which has led to the destruction of many bridges and roads and localized severe flooding.
 
Total gold exported during Q1-2017 was 20,301 oz. 
Monthly gold production data in 2017 and 2016 for the first quarter are presented in the Table 1 below. As compared to 2016, gold production was higher in January (+15%) and reached an all-time high for a month of February (+31%) but due to the extreme weather and its impact, production was lower in March (-16%). Nevertheless, total quarterly gold production increased by 8.3% (1,318 oz). 
Read more: Dynacor Gold Mines ( DNG )

Ceapro Inc. Reports 2016 Financial Results and Provides Corporate Update

Company reports highest full year revenues in Company's history and continues to deliver strong performance
 
EDMONTON, ALBERTA--(April 6, 2017) -Ceapro Inc.(TSX VENTURE:CZO)("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve months ended December 31, 2016 and provided a corporate update. The Company's 2016 financial results reveal the best year in Ceapro's history.
 
Financial Highlights for the Full Year 2016
Highest full year revenue and operating cash flows in Company's history;
Total sales of $13,674,000 for the full year 2016 compared to $10,667,000 in 2015, an increase of 28.2% year-over-year revenue performance;
Read more: Ceapro Inc ( CZO )

Akers Biosciences Begins Selling Rapid Cholesterol Test through Distribution Agreement with First Check

THOROFARE, NJ--(Marketwired - Mar 28, 2017) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has received an initial order for the Company's rapid cholesterol self-test from First Check Diagnostics, LLC ("First Check"), the exclusive distributor for this product in the United States, for sale under their popular "First Check" brand.
 
First Check products are sold through major retailers including, CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop & Shop, Giant and ShopKo.
 
Akers Bio's Tri-Cholesterol "Check" test is the only combined rapid test which provides an estimate of a person's Total cholesterol as well as their High Density Lipoprotein ("HDL") cholesterol levels - their 'good cholesterol'; thereby providing an estimate of a person's Low Density Lipoprotein ("LDL") levels - their 'bad cholesterol'. These features are essential to accurately differentiating between a person's 'good' and 'bad' cholesterol thereby making it a truly effective screening test for high cholesterol.
Read more: Akers Biosciences ( AKER )

Groupon Announces Fourth Quarter and Fiscal Year 2016 Results

2017-02-15 08:31 ET - News Release
 
Added 5.2 million net new customers and achieved double digit Gross Profit growth in North America for 2016
 
Fourth quarter revenue of $934.9 million, $3.1 billion for the full year
Fourth quarter gross billings of $1.7 billion, $6.1 billion for the full year
Fourth quarter net loss of $50.2 million, $183.3 million for the full year
Fourth quarter Adjusted EBITDA of $80.6 million, $178.1 million for the full year
Fourth quarter loss per share of $0.09; non-GAAP earnings per share of $0.07
Read more: Groupon Inc ( GRPN )

FDA Exempts Evoke from Requirement for Human Factor Validation Study

SOLANA BEACH, Calif., Feb. 15, 2017  -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that it has received a letter from FDA exempting its late stage product, Gimoti™ from a Human Factors (HF) Validation study requirement prior to submission of a New Drug Application (NDA).
 
In February 2016, FDA published new guidance entitled “Applying Human Factors and Usability Engineering to Medical Devices”, which requires drug products classified as a drug/device combination, such as Gimoti, undergo evaluation that may require an HF Validation study as described in FDA’s Guidance. 
Read more: Evoke Pharma Inc ( EVOK )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker